Liminatus Pharma (LIMN) Change in Accured Expenses (2024 - 2026)
Liminatus Pharma (LIMN) posted Change in Accured Expenses of -$191956.0 for Q1 2026, down 932.28% sequentially from $23064.0 in Q4 2025, and down 258.03% YoY from $121467.0 in Q1 2025.
Liminatus Pharma (LIMN) Change in Accured Expenses (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Change in Accured Expenses for 3 years, with the latest figure at -$191956.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 258.03% year-over-year to -$191956.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.3 million (down 4036.49% YoY) and the FY2025 annual result came in at -$4.0 million, down 37448.53% from the prior year.
- Change in Accured Expenses declined to -$191956.0 in Q1 2026 per LIMN's latest filing, from $23064.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $121467.0 in Q1 2025 and troughed at -$2.2 million in Q2 2025.
- A 3-year average of -$529786.2 and a median of -$20455.0 in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 22.9% in 2025, down 11070.24% in 2025.
- Over 3 years, Change in Accured Expenses stood at $29916.0 in 2024, then decreased by 22.9% to $23064.0 in 2025, then tumbled by 932.28% to -$191956.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$191956.0, $23064.0, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | -102,128.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -191,956.00 |
| Mar 31, 2026 | -191,956.00 |
| Dec 31, 2025 | 23,064.00 |
| Dec 31, 2025 | 23,064.00 |
| Sep 30, 2025 | -2.01 Mn |
| Sep 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Mar 31, 2025 | 121,467.00 |
| Mar 31, 2025 | 121,467.00 |
| Dec 31, 2024 | 29,916.00 |
| Dec 31, 2024 | 29,916.00 |
| Sep 30, 2024 | -18,039.00 |
| Sep 30, 2024 | -18,039.00 |
| Jun 30, 2024 | -22,871.00 |
| Jun 30, 2024 | -22,871.00 |